AAVantgarde Bio - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Tata Power targets 2.8 GW data-centre opportunity pipeline as Rs 15,000cr Mumbai grid plan advances

Fluence wins Vattenfall’s 1 GWh German battery storage contract as shares face pressure

Essar Oil & Gas adds five CBM blocks with 6.6 Tcf of gas in place

Essar Oil & Gas secures five coal-bed methane blocks with 6.6 Tcf gas-in-place potential

Editorial infographic showing an oil refinery at sunset with market-style chart lines and key ExxonMobil Q3 2026 indicators, including a $4.5 billion refining-margin uplift, a $1.3 billion upstream hit from lower liquids prices, a $2.5 billion timing effect, and an October 30, 2026 results date.

ExxonMobil signals $4.5bn refining earnings boost as oil-price pressure hits upstream

Read More

Pharma Industry News

AAVantgarde clears key execution hurdle as LUCE-1 Phase 1/2 study of AAVB-081 completes enrollment

Find out how AAVantgarde Bio’s LUCE-1 enrollment milestone reshapes the gene therapy landscape for Usher syndrome type B retinitis pigmentosa.

bySoujanya Ravi

January 18, 2026

web analytics